GLOBAL RESPONSE
agency: Juice Pharma Advertising
brand: Gardasil
client: Merck
photo from left: Adam Kline, VP, associate creative director • Debra Strober, group copy supervisor • Stacie Cavallaro, VP, account supervisor • Forrest King, EVP, managing partner, executive creative director • Annie Foster, group art supervisor
Some drugs are so desperately needed, that when they're introduced, it's like a shot heard round the world. Such was the case with Merck's cancer vaccine, Gardasil. But how does one craft a professional marketing campaign that communicates the product's promise—something that doctors everywhere can relate to?
Juice Pharma Advertising managed to pull off the global effort, taking care to strike an appropriate emotional note that transcended culture and succeeded in addressing the need to vaccinate young girls to prevent them from cancer-causing sexually transmitted diseases.
"We have one brand personality that is carried throughout the whole world," says Adam Kline of Juice. "You have this cohesion so that all the markets can relate to it."
Juice executed an upbeat, visually dynamic campaign, relying on a striking color palette and illustrative style to communicate information about Gardasil. In doing so, Juice managed to match the brand's great expectations with an equally strong delivery.
PREVIOUS AGENCY ‹‹ HOME ›› NEXT AGENCY
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.